Table 3.

Antibiotic non-susceptibility (resistant plus intermediate).

	OXA-48		VIM-1		KPC-3		NDM-1
	CI	TC	CI	TC	CI	TC	CI	TC
	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)
Amoxicillin-Clavulanate	48 (100)	48 (100)	12 (100)	12 (100)	2 (100)	2 (100)	4 (100)	3 (100)
Piperacillin- tazobactam	48 (100)	48 (100)	12 (100)	12 (100)	2 (100)	2 (100)	4 (100)	3 (100)
Cefotaxime	34 (70.8)	10 (20.8)	12 (100)	12 (100)	2 (100)	2 (100)	4 (100)	3 (100)
Ceftazidime	30 (62.5)	10 (20.8)	12 (100)	12 (100)	2 (100)	2 (100)	4 (100)	3 (100)
Cefepime	27 (56.2)	6 (12.5)	12 (100)	12 (100)	2 (100)	2 (100)	4 (100)	3 (100)
Aztreonam	28 (58.3)	8 (16.7)	5 (41.7)	3 (25)	2 (100)	2 (100)	4 (100)	0 (0)
Imipenem	9 (18.7)	12 (25)	6 (50)	5 (41.7)	2 (100)	2 (100)	4 (100)	3 (100)
Meropenem	31 (64.6)	8 (16.7)	7 (58.3)	2 (16.7)	2 (100)	2 (100)	4 (100)	3 (100)
Ertapenem	48 (100)	28 (58.3)	8 (66.7)	3 (25)	2 (100)	2 (100)	4 (100)	3 (100)
Gentamicin	25 (52.1)	2 (4.2)	4 (33.3)	0 (0)	0 (0)	0 (0)	4 (100)	3 (100)
Tobramycin	25 (52.1)	1 (2.1)	11 (91.6)	0 (0)	0 (0)	0 (0)	4 (100)	3 (100)
Amikacin	1 (2.1)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	3 (75)	3 (100)
Ciprofloxacin	32 (66.7)	1 (2.1)	7 (58.3)	1 (8.3)	2 (100)	0 (0)	4 (100)	0 (0)
Sulfamethoxazole trimethoprim	31 (64.6)	1 (2.1)	8 (66.7)	1 (8.3)	2 (100)	0 (0)	1 (25)	0 (0)
Tigecycline	2 (4.2)	1 (2.1)	2 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Fosfomycin	36 (75)	0 (0)	7 (58.3)	0 (0)	2 (100)	0 (0)	3 (75)	0 (0)
Colistin	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

(CI = Clinical isolates; TC = Transconjugant).